Second- or third-generation tyrosine kinase inhibitors in first-line treatment of chronic myeloid leukemia in general population: Is there a real benefit?
Fiche publication
Date publication
septembre 2021
Journal
Cancer medicine
Auteurs
Membres identifiés du Cancéropôle Est :
Pr MAYNADIE Marc
Tous les auteurs :
Canet J, Cony-Makhoul P, Orazio S, Cornet E, Troussard X, Maynadié M, Étienne G, Monnereau A
Lien Pubmed
Résumé
Since 2009, multiple randomized trials have shown faster and deeper responses in CML patients treated with new-generation TKI (NG-TKI) compared to those treated with imatinib (IM). Are the same results observed in the general population?
Mots clés
chronic myeloid leukemia, observational study, population-based cancer registries, real life, tyrosine kinase inhibitor
Référence
Cancer Med. 2021 Sep 22;: